| 利妥昔单抗治疗类风湿关节炎的临床研究进展 |
| |
| 引用本文： | 赵义,栗占国. 利妥昔单抗治疗类风湿关节炎的临床研究进展[J]. 中国新药杂志, 2006, 15(11): 848-852 |
| |
| 作者姓名： | 赵义 栗占国 |
| |
| 作者单位： | 北京大学人民医院风湿免疫科,北京,100044 |
| |
| 摘 要： | 利妥昔单抗是一种特异性针对CD20分子的基因工程抗体,能与B淋巴细胞表面的CD20结合,并通过补体介导的细胞毒作用等机制对B淋巴细胞进行特异性清除,从而达到治疗作用.利妥昔单抗最初作为抗淋巴瘤药物首先获得美国FDA认证,近年来被应用于类风湿关节炎等自身免疫病的治疗,取得了较好的疗效.现对其治疗类风湿关节炎的作用机制、临床应用和研究进展做一综述.
|
| 关 键 词： | 利妥昔单抗 类风湿关节炎 B淋巴细胞 |
| 文章编号： | 1003-3734（2006）11-0848-05 |
| 收稿时间： | 2006-02-10 |
| 修稿时间： | 2006-02-10 |
Clinical application of rituximab in rheumatoid arthritis |
| |
| ZHAO Yi,LI Zhan-guo. Clinical application of rituximab in rheumatoid arthritis[J]. Chinese Journal of New Drugs, 2006, 15(11): 848-852 |
| |
| Authors: | ZHAO Yi LI Zhan-guo |
| |
| Abstract: | Rituximab is a new therapeutic monoclonal antibody against CD20, an antigen expressed by B cells but not B-cell progenitor or plasma cells. It was previously approved for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) and was well tolerated and efficacious. Currently, several open-label studies and two double-blind, randomized controlled trials showed that rituximab could lead to sustained benefits for patients with active rheumatoid arthritis (RA). This article briefly reviews the mechanism and clinical experiences of rituximab in RA. |
| |
| Keywords: | rituximab rheumatoid arthritis B lymphocytes |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
